All eyes will be on Glaukos Corp. as the $2.5 billion valued firm works to integrate its largest acquisition to date, Avedro Inc., following an all-stock deal that closed last month.
It gives San Clemente-based Glaukos access to Avedro’s FDA-approved Photrexa keratoconus therapy, used to prevent worsening of a certain type of corneal disease.
Avedro’s shareholders now own about 15% of the combined company.
“Avedro will serve as the cornerstone of our new corneal health franchise,” Tom Burns, Glaukos president and CEO, said at the time the deal closed. “This transaction pairs two highly complementary, hybrid pharma and device organizations.”
Glaukos is best known for the iStent device to treat mild-to-moderate open-angle glaucoma. It is expected to complete its headquarters move to Aliso Viejo shortly.
